Figure 1From: Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104)Measurement of FT activity in tumor biopsies pre-treatment compared to on-therapy. Excisional biopsies of cutaneous melanoma metastases obtained prior to therapy with R115777 and during week 7 of therapy were cryopreserved until analysis. FT activity was assessed as described in Materials and Methods. All post-treatment values were statistically significantly inhibited using an unpaired t-test (p<0.01). The assay was performed on single tumors in triplicate, and the error bars represent the variation in the assay for each sample.Back to article page